R&D Pipeline

With radioligand therapy (RLT) at the core of its strategy, StarRay focuses on the discovery, development, and clinical translation of theranostic radiopharmaceuticals for oncology. The Company continuously advances the development of a differentiated R&D pipeline, and is committed to delivering safe, precise, and accessible diagnostic and therapeutic solutions to patients worldwide.